Vivian to represent LEO Pharma
Partnership brings specialist dermatology treatments to Malta
Vivian has partnered with global dermatology leader LEO Pharma to bring advanced skin treatments to Maltese patients, improving access to therapies for chronic conditions such as psoriasis and eczema. These conditions affect thousands in Malta and can significantly impact quality of life.
Psoriasis, a dry and scaly skin condition, affects around 5.1 million Europeans and approximately 5% of Malta’s population. Eczema, characterised by rashes, redness, inflammation and dry skin, affects 10-15% of Maltese children and about 5% of adults.
Headquartered in Denmark and owned by the LEO Foundation, LEO Pharma operates in more than 130 countries and is internationally recognised for its research and innovation in dermatology.
“Our collaboration with LEO Pharma represents a major step forward in making specialist dermatology treatments more accessible to Maltese patients,” Yan Grima, general manager of Vivian, said.
“By combining LEO Pharma’s innovation with our local expertise, we can now ensure that thousands of patients can receive timely access to the care they need.”
Denise Borg Manché, managing director of Vivian, added: “This partnership reflects our ongoing commitment to expanding access to therapies that address chronic conditions. We will continue working closely with health authorities, healthcare professionals and patient organisations to translate innovation into real-world improvements.”
Paolo Pozzolini, general manager, LEO Pharma Italy, noted: “We chose Vivian for their strong local presence, deep market knowledge, and proven commitment to patient access. Their longstanding relationships within Malta’s healthcare system make them an ideal partner to deliver our innovative treatments to those who need them most.”